Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients (ADDIT-GLIO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02649582|
Recruitment Status : Recruiting
First Posted : January 7, 2016
Last Update Posted : May 24, 2018
|Condition or disease||Intervention/treatment||Phase|
|Glioblastoma Multiforme of Brain||Biological: Dendritic cell vaccine plus temozolomide chemotherapy||Phase 1 Phase 2|
Glioblastoma multiforme (GBM), a microscopically infiltrative disease, is the most common malignant brain tumor worldwide. Despite optimized standard of care treatment median survival and prognosis remain poor with a median survival of only 15% and five year survival after diagnosis of 5%.
In this single arm single centre phase I/II trial the investigators will determine the overall and progression free survival of patients with newly diagnosed GBM when autologous WT1 mRNA loaded dendritic cell vaccination is added to standard of care treatment. During two years of recruitment the investigators will include 20 patients with newly diagnosed, histologically verified glioblastoma (WHO grade IV) who have received a total or subtotal resection of the tumor. Patients who underwent prior radiation or chemotherapy or with a history of other malignancy will be excluded. In addition to standard of care consisting of adjuvant chemoradiation with temozolomide and temozolomide maintenance patients will receive an intradermal vaccination with autologous WT1 mRNA-loaded dendritic cells commencing 1 week after radiotherapy. The dendritic cell therapy product will be generated and administered in the Antwerp University Hospital, more specifically the Center for Cell Therapy and Regenerative Medicine (CCRG) and the Division of Hematology, both headed by Prof. Zwi Berneman.
Recruitment began in December 2015 and is intended to continue until the end of 2020 or when 20 patients are enrolled. After 2 years of follow up (expected until 2022) overall and progression free survival analysis will be performed and this will be compared with the published data of standard of care treatment without vaccination. In addition the investigators will look for feasibility, incidence of adverse events and immunogenicity.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Adjuvant Dendritic-Cell Immunotherapy Plus Temozolomide Following Surgery and Chemoradiation in Patients With Newly Diagnosed Glioblastoma|
|Actual Study Start Date :||December 2015|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2022|
Experimental: Single Arm
Dendritic cell vaccine plus temozolomide chemotherapy
Biological: Dendritic cell vaccine plus temozolomide chemotherapy
When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):
- Overall survival [ Time Frame: Through study completion (anticipated 2 years) with 2-year follow-up ]Patients will be followed for survival, from apheresis (~ diagnosis), for which the accurate date and reason of death (cancer-related or non-related) will be recorded for every patient.
- Number of glioblastoma patients post surgical resection with feasible and safe DC vaccine production [ Time Frame: Vaccine production and quality testing (i.e. 4 weeks after leukapheresis) ]
Production of autologous DC vaccines from newly diagnosed glioblastoma patients that underwent maximal, safe surgical resection will be evaluated for:
- feasibility, assessed by success of leukapheresis and production of sufficient and qualified (phenotypic and functional requirements) vaccines.
- Safety, assessed by microbiological testing (bacteria, yeast, fungi, mycoplasma, endotoxin) of the DC vaccines.
- Feasibility of DC vaccine administration to glioblastoma patients combined with chemotherapy [ Time Frame: Upon maintenance chemotherapy treatment (i.e. +/- 12 weeks post leukapheresis) ]Administration of 3 weekly DC vaccines following adjuvant chemoradiation (induction phase) and additional DC vaccination at day 21 of each maintenance chemotherapy cycle (booster phase) will be evaluated for feasibility, assessed by successful DC vaccine administration of the proposed treatment scheme.
- Number of participants with adverse events as a measure of safety and tolerability [ Time Frame: Through study completion (anticipated 2 years) with 2-year follow-up ]Monitoring the incidence of adverse events to evaluate the safety profile and tolerability of the treatment. The severity of adverse events will be assessed according to the NCI CTCAE scale (v4.03, published June 14, 2010).
- Immunological responses to the DC vaccine [ Time Frame: At first DC vaccination + day 1 of first and fourth temozolomide treatment cycles ]Immunological responses to the vaccine will be evaluated ex vivo. Blood samples will be collected from patients on the day of the first DC vaccine, and on day 1 of the first and fourth maintenance temozolomide treatment cycles and will be examined for cell subset distribution and activation status and antigen-specific immunity.
- Objective clinical responses by tumor evaluation (clinical efficacy) [ Time Frame: Through study completion (anticipated 2 years) with 2-year follow-up ]
Disease evolution and progression-free survival will be assessed according to the Response Assessment in Neuro-Oncology (RANO) criteria, based on imaging findings (MRI, CT), clinical status and corticosteroid use.
Disease will be assessed following chemoradiation (≤ 2 weeks after completing chemoradiation), after every two cycles of temozolomide maintenance treatment and at least every 12 weeks during the booster phase, and every 9-12 weeks during follow-up after treatment discontinuation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02649582
|Contact: Zwi N Berneman, MD, PhD||0032 3 821 39 email@example.com|
|Contact: Pol Specenier, MD, PhD||0032 3 821 40 firstname.lastname@example.org|
|Antwerp University Hospital||Recruiting|
|Edegem, Antwerp, Belgium, 2650|
|Contact: Zwi N Berneman, MD, PhD email@example.com|
|Contact: Pol Specenier, MD, PhD 038214014 ext 0032 firstname.lastname@example.org|
|Study Director:||Zwi N Berneman, MD, PhD||Antwerp University Hospital, Division of Hematology and Center for Cell Therapy and Regenerative Medicine|
|Principal Investigator:||Pol Specenier, MD, PhD||Antwerp University Hospital (UZA), Division of Oncology|
|Principal Investigator:||Yannick Willemen, MD||University of Antwerp, Laboratory of Experimental Hematology|
|Principal Investigator:||Evelien LJ Smits, MSc, PhD||University of Antwerp, Laboratory of Experimental Hematology|
|OverallOfficial:||Barbara Stein, MSc||Antwerp University Hospital, Division of Hematology|
|OverallOfficial:||Eva Lion, MSc, PhD||University of Antwerp, Laboratory of Experimental Hematology|